HS-20093 + bevacizumab + oxaliplatin + 5-fluorouracil + leucovorin

This is a combination regimen consisting of: - **HS-20093**: a fully humanized IgG1 antibody-drug conjugate (ADC) targeting B7-H3, overexpressed on solid tumor cells, with a mechanism involving targeted cytotoxic delivery[1][3][5][7]; - **bevacizumab**: a humanized monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), blocking angiogenesis[2][4][8]; - **oxaliplatin**: a platinum-based chemotherapeutic causing DNA crosslinking and apoptosis in rapidly dividing cells; - **5-fluorouracil**: a pyrimidine antimetabolite that inhibits thymidylate synthase, disrupting DNA synthesis; - **leucovorin**: a reduced folate used to enhance the effects of 5-fluorouracil. This regimen is primarily investigated for advanced solid tumors, including small cell lung cancer and potentially other indications, leveraging cytotoxic, antiangiogenic, and targeted mechanisms.